S0022:Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer

Launched by SWOG CANCER RESEARCH NETWORK · Jan 26, 2003

Keywords

ClinConnect Summary

OBJECTIVES:

* Determine survival and time to treatment failure in patients with stage IIIB non-small cell lung cancer treated with induction docetaxel, cisplatin, and radiotherapy followed by consolidation docetaxel.
* Determine the response rate in these patients when treated with this regimen.
* Determine the toxic effects of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive induction chemotherapy comprising docetaxel IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 and cisplatin IV over 60 minutes on days 1, 8, 29, and 36. Patients also undergo ...

Gender

ALL

Eligibility criteria

• DISEASE CHARACTERISTICS:
• • Histologically or cytologically confirmed stage IIIB non-small cell lung cancer
• • Adenocarcinoma
• • Large cell carcinoma
• • Squamous cell carcinoma
• • Pathologically or radiographically documented positive N3 nodes
• • No positive supraclavicular or scalene lymph nodes with disease extending into the cervical region OR
• * T4 tumor invading any of the following:
• • Mediastinum
• • Heart
• • Great vessels
• • Trachea
• • Esophagus
• • Vertebral body
• • Carina
• • No brain, contralateral chest, liver, or adrenal metastases
• • No more than 1 parenchymal lesion
• • No malignant pleural effusions unless they are only visible on CT scan or deemed too small to tap
• • No pericardial effusions
• • Measurable disease
• PATIENT CHARACTERISTICS:
• Age:
• • 18 and over
• Performance status:
• • Zubrod 0-2
• Life expectancy:
• • Not specified
• Hematopoietic:
• • Absolute neutrophil count at least 1,500/mm\^3
• • Platelet count at least 100,000/mm\^3
• Hepatic:
• • Not specified
• Renal:
• • Creatinine clearance at least 50 mL/min
• Pulmonary:
• * One of the following:
• • FEV1 at least 2.0 L
• • Predicted FEV1 of contralateral lung greater than 800 mL
• • Predicted post-treatment FEV1 at least 1.0 L
• Other:
• • No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• • Not pregnant or nursing
• • Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• • No concurrent growth factors during induction chemoradiotherapy
• Chemotherapy:
• • No prior chemotherapy for lung cancer
• Endocrine therapy:
• • Not specified
• Radiotherapy:
• • No prior radiotherapy for lung cancer
• Surgery:
• • No prior surgical resection of lung cancer
• • Prior exploratory thoracotomy, mediastinoscopy, excisional biopsy, or similar surgery for determining diagnosis, stage, or potential resectability allowed